Aprea Therapeutics to Outline Pipeline Progress at Oppenheimer Healthcare Conference—Lead Programs Target Multiple Tumor Types
Market Chameleon (Wed, 18-Feb 11:53 AM)
Aprea’s WEE1 Inhibitor APR-1051 Shows Early Promise: Partial Response Observed in Endometrial Cancer Trial
Market Chameleon (Fri, 30-Jan 11:06 AM)
